Thus, hPL inhibitors can reduce the hydrolysis of dietary lipids in the gastrointestinal tract by decreasing the hydrolytic activity of hPL, thereby alleviating the symptoms of obesity and overweight [11,12,13]. This evidence concerns the gene LGALS1 and obesity due to melanocortin 4 receptor deficiency.